MGP
RPRX icon

Metis Global Partners’s Royalty Pharma RPRX Stock Holding History

Metis Global Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.33M Sell
59,374
-1,166
-2% -$60.7K 0.08% 205
2026
Q1 		$2.9M Sell
60,540
-3,750
-6% -$164K 0.07% 226
2025
Q4 		$2.48M Sell
64,290
-946
-1% -$36.1K 0.06% 271
2025
Q3 		$2.3M Sell
65,236
-2,644
-4% -$95.7K 0.05% 297
2025
Q2 		$2.45M Buy
67,880
+30,959
+84% +$1.03M 0.06% 269
2025
Q1 		$1.15M Buy
36,921
+1,060
+3% +$33.6K 0.03% 434
2024
Q4 		$915K Buy
35,861
+14,124
+65% +$375K 0.03% 456
2024
Q3 		$615K Buy
21,737
+2,126
+11% +$58.9K 0.02% 531
2024
Q2 		$517K Buy
19,611
+6,065
+45% +$168K 0.02% 534
2024
Q1 		$411K Buy
13,546
+179
+1% +$5.28K 0.01% 596
2023
Q4 		$375K Buy
+13,367
New +$367K 0.02% 608

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Metis Global Partners's RPRX Position: Q2 2026 in Review

Metis Global Partners reduced its Royalty Pharma (RPRX) stake by 1.9% in Q2 2026, selling an estimated $60.7K and leaving 59,374 shares worth $3.33M. The position accounts for 0.08% of the portfolio, ranked #205.

Metis Global Partners first reported a position in RPRX in Q4 2023 and has held it in 11 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Metis Global Partners held 59,374 shares of Royalty Pharma worth $3.33M as of Q2 2026.
  • Metis Global Partners sold 1,166 Royalty Pharma shares in Q2 2026, an estimated $60.7K.
  • Royalty Pharma made up 0.08% of Metis Global Partners's portfolio in Q2 2026, its #205 holding.
  • Metis Global Partners first reported a position in Royalty Pharma in Q4 2023 and has held it in 11 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Metis Global Partners's 13F filing for Q2 2026, filed 10 Aug 2026.